NMeFOSAA

NMeFOSAA enters drinking water through the same three pathways as NEtFOSAA: (1) direct industrial discharges from former 3M and licensee manufacturing facilities, (2) leachate from landfills that received 3M-coated consumer products before the 2002 phaseout, and (3) atmospheric deposition and groundwater migration from aqueous film-forming foam (AFFF) release sites where the parent MeFOSE and MeFOSA chemistries were used. Because NMeFOSAA biotransforms over months-to-years into PFOS, sites with elevated NMeFOSAA today typically also show elevated PFOS in groundwater and serum. The Massachusetts cluster — 87 of 144 utilities — reflects both the state's dense industrial history and its proactive PFAS testing program; outside MA, the highest U.S. level (9.55 ppt at Montevallo, AL) and the chronic-source pattern at Seekonk, MA (16 of 21 tests positive at 1.51 ppt) both point to identifiable upgradient industrial or AFFF source areas.

NMeFOSAA has not been formally classified as a carcinogen by IARC or NTP, and its standalone toxicological dataset is smaller than that of its terminal degradation product PFOS. The principal health concern is that NMeFOSAA serves as a body-burden source of PFOS: once ingested it undergoes slow oxidative biotransformation in the liver to perfluorooctanesulfonate, contributing to lifetime PFOS exposure and the well-documented PFOS endpoints — immune suppression, hepatotoxicity, thyroid disruption, developmental effects, and elevated cholesterol. Direct in-vitro and animal studies of NMeFOSAA itself have also reported hepatic, endocrine, and developmental effects at moderate doses. NMeFOSAA is monitored under UCMR 5 but is not currently subject to a federal MCL.

NMeFOSAA is removed effectively by granular activated carbon (GAC), anion exchange resin, and high-pressure membranes including reverse osmosis and nanofiltration. Its long perfluorinated chain and ionizable carboxylate group give it strong adsorption affinity on GAC media — comparable to its ethyl sibling NEtFOSAA and to PFOS itself. Conventional treatment processes — coagulation, sand filtration, disinfection, UV, and ozonation — do not remove it. Boiling concentrates rather than removes it. NSF/ANSI 53 and NSF P473 certify point-of-use filters for PFAS reduction; NSF/ANSI 58 covers RO systems. Treatment plants targeting NMeFOSAA should also expect simultaneous removal of the parent compounds MeFOSA, MeFOSE, and the PFOS daughter product.